加载中
HKSEHealthcareBiotechnology
最新数据
HK$27.86
−HK$0.66 · -2.31%
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
最新数据
HK$27.86
−HK$0.66 · -2.31%
盘中时间采用HKT。市场数据可能有所延迟。
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
日内区间
当前HK$27.86
52周区间
当前HK$27.86
盘中时间采用HKT。市场数据可能有所延迟。
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
日内区间
当前HK$27.86
52周区间
当前HK$27.86
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CNY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 140.95亿 CNY | 122.76亿 CNY | 115.38亿 CNY | 102.66亿 CNY | 74.44亿 CNY |
| 销货成本 | 91.85亿 CNY | 80.73亿 CNY | 74.14亿 CNY | 64.98亿 CNY | 47.65亿 CNY |
| 毛利 | 49.1亿 CNY | 42.03亿 CNY | 41.24亿 CNY | 37.68亿 CNY | 26.79亿 CNY |
| 研究与开发 | 5.76亿 CNY | 4.69亿 CNY | 4.48亿 CNY | 2.82亿 CNY | 1.52亿 CNY |
| 销售、一般及管理费用 | 7.89亿 CNY | 7.21亿 CNY | 18.59亿 CNY | 9.69亿 CNY | 4.1亿 CNY |
| 营业费用 | 29.81亿 CNY | 20.99亿 CNY | 22.77亿 CNY | 20.18亿 CNY | 11.54亿 CNY |
| 利息收入 | 3939.07万 CNY | 7363.14万 CNY | 2993.37万 CNY | 3521.31万 CNY | 6440.69万 CNY |
| 利息支出 | 1.93亿 CNY | 2.44亿 CNY | 1.82亿 CNY | 1.67亿 CNY | 8307.35万 CNY |
| 折旧和摊销 | 11.81亿 CNY | 10.49亿 CNY | 9.27亿 CNY | 6.96亿 CNY | 4.98亿 CNY |
| 营业利润 | 19.28亿 CNY | 21.04亿 CNY | 18.48亿 CNY | 16.9亿 CNY | 19.14亿 CNY |
| 净利润 | 16.64亿 CNY | 17.93亿 CNY | 16.01亿 CNY | 13.75亿 CNY | 16.61亿 CNY |
公司数据更新于 2026年10月14日。
近期已公布业绩
近期已公布业绩
年度分割调整后的每股现金分配。
HK$0.2188
2025年（完整年度）+35.7% 自从 2021
2026年（部分年度）：HK$0.2299
HK$0.1612
2,021
HK$0.3522
2,022
HK$0.3286
2,023
HK$0.2199
2,024
HK$0.2188
2,025
HK$0.2299
2,026*
* 在现有股息历史记录中，该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年7月7日 | HK$0.2299Annual | 2026年7月8日 | 2026年8月7日 |
股息 | 2025年7月4日 | HK$0.2188Annual | 2025年7月7日 | 2025年8月6日 |
股息 | 2024年6月27日 | HK$0.2199Annual | 2024年6月28日 | 2024年7月26日 |
股息 | 2023年7月18日 | HK$0.3286Annual | 2023年7月19日 | 2023年8月18日 |
股息 | 2022年6月6日 | HK$0.5283Annual | 2022年6月7日 | 2022年7月12日 |
股息 | 2021年6月1日 | HK$0.3626Annual | 2021年6月2日 | 2021年7月15日 |
除息 2026年7月7日
HK$0.2299
Annual
2026年7月8日登记 · 支付日 2026年8月7日
除息 2025年7月4日
HK$0.2188
Annual
2025年7月7日登记 · 支付日 2025年8月6日
除息 2024年6月27日
HK$0.2199
Annual
2024年6月28日登记 · 支付日 2024年7月26日
除息 2023年7月18日
HK$0.3286
Annual
2023年7月19日登记 · 支付日 2023年8月18日
除息 2022年6月6日
HK$0.5283
Annual
2022年6月7日登记 · 支付日 2022年7月12日
除息 2021年6月1日
HK$0.3626
Annual
2021年6月2日登记 · 支付日 2021年7月15日
报告持有此股票敞口的交易所交易基金。
Vanguard FTSE Emerging Markets ETFVWO1818.92万0.01%1685亿 USD0.06%US$59.18-0.84%
Vanguard Total International Stock ETFVXUS1818.76万0.00%6657亿 USD0.05%US$83.965-0.68%
Vanguard FTSE All-World ex-US ETFVEU303.23万0.00%986亿 USD0.04%US$82.06-0.66%
First Trust Emerging Markets AlphaDEX FundFEM169.72万0.21%8.18亿 USD0.80%US$32.875-0.77%
Schwab Emerging Markets Equity ETFSCHE163.89万0.01%127.98亿 USD0.06%US$36.355-0.90%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM124.82万0.01%94.46亿 USD0.39%US$39.04-1.06%
Vanguard Total World Stock ETFVT103.29万0.00%1017亿 USD0.06%US$158.74-0.64%
WisdomTree China ex-State-Owned Enterprises FundCXSE83.83万0.19%4.49亿 USD0.32%US$33.8301-1.54%Vanguard FTSE Emerging Markets ETFVWOVanguard Total International Stock ETFVXUSVanguard FTSE All-World ex-US ETFVEUFirst Trust Emerging Markets AlphaDEX FundFEMSchwab Emerging Markets Equity ETFSCHEDimensional - Emerging Markets Core Equity 2 ETFDFEMVanguard Total World Stock ETFVTWisdomTree China ex-State-Owned Enterprises FundCXSEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
